

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/Capplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/Capplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/Capplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/Capplus enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/Capplus fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/Capplus(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:16:09 ON 29 SEP 2006

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'MEDLINE' ENTERED AT 17:18:51 ON 29 SEP 2006

FILE 'USPATFULL' ENTERED AT 17:18:51 ON 29 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:18:51 ON 29 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 17:18:51 ON 29 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:18:51 ON 29 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 17:18:51 ON 29 SEP 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'BIOSIS' ENTERED AT 17:18:51 ON 29 SEP 2006
Copyright (c) 2006 The Thomson Corporation

=> s peptide and (decrease type II collagen degradation)
L1 0 PEPTIDE AND (DECREASE TYPE II COLLAGEN DEGRADATION)

=> s peptide and (decrease chondrocyte hypertrophy)
L2 0 PEPTIDE AND (DECREASE CHONDROCYTE HYPERTROPHY)

=> e Poole, r/au
E1 1 POOLE WOLSON P A/AU
E2 3 POOLE ZOBEL B L/AU
E3 0 --> POOLE, R/AU
E4 1 POOLEN L J V/AU
E5 1 POOLEN LAMBERT J VAN/AU
E6 1 POOLER A/AU
E7 1 POOLER A F W M/AU
E8 15 POOLER A M/AU
E9 1 POOLER AFWM/AU
E10 10 POOLER AMY M/AU
E11 2 POOLER ARCHBOLD G/AU
E12 1 POOLER ARCHBOLD H A/AU

=> s peptide and hydroxylation
L3 11499 PEPTIDE AND HYDROXYLATION

=> s l3 and (Gly-X-Pro)
L4 5 L3 AND (GLY-X-PRO)

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 5 USPATFULL on STN
TI Methods for the diagnosis and treatment of bone disorders
AB This invention pertains to chemometric methods for the analysis of
chemical, biochemical, and biological data, for example, spectral data,
for example, nuclear magnetic resonance (NMR) spectra, and their
applications, including, e.g., classification, diagnosis, prognosis,

etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:307072 USPATFULL
TITLE: Methods for the diagnosis and treatment of bone disorders
INVENTOR(S): Nicholson, Jeremy Kirk, Croydon, UNITED KINGDOM
Holmes, Elaine, London, UNITED KINGDOM
Lindon, John Christopher, Westerham, UNITED KINGDOM
Brindle, Joanne Tracey, Watchfield, UNITED KINGDOM
Grainger, David John, Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004241743	A1	20041202
APPLICATION INFO.:	US 2004-475791	A1	20040712 (10)
	WO 2002-GB1909		20020423

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-9930	20010423
	GB 2001-17428	20010717
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	4866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 5 USPATFULL on STN

TI Products for regulating the degradation of collagen and methods for identifying same

AB The present invention provides products and methods for regulating the degradation of collagen, including type II collagen. Also encompassed are variants, inhibitors, and mimetics of type II collagen peptide fragments and inhibitors of the proteases producing these peptide fragments that are capable of modifying the degradation of collagen whereby the pathological effects of increased collagen destruction are reduced. In addition, the present invention provides methods for treating disease states wherein the disease state results directly or indirectly from the degradation of one or more collagen species. Furthermore, the present invention encompasses the screening of these peptide fragments for diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:159405 USPATFULL
TITLE: Products for regulating the degradation of collagen and methods for identifying same
INVENTOR(S): Poole, A. Robin, South Lancaster, CANADA
PATENT ASSIGNEE(S): Shriners Hospital For Children (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122209	A1	20040624
APPLICATION INFO.:	US 2003-674065	A1	20030930 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414332P	20020930 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,
WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 92
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2184
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 5 USPATFULL on STN

TI DNA encoding a novel serum protein produced exclusively in adipocytes
AB The present invention relates to DNA encoding Acrp30, of vertebrate
(e.g., mammalian) origin, and particularly of human and rodent origin.
The present invention further relates to isolated, recombinantly
produced or synthetic DNA which hybridizes to the nucleotide sequences
described herein and RNA transcribed from the nucleotides sequence
described herein. In addition, the invention relates to expression
vectors comprising DNA encoding Acrp30, which is expressed when the
vector is present in an appropriate host cell. The invention further
relates to isolated, recombinantly produced or synthetic mammalian
Acrp30 of vertebrate (e.g., mammalian) origin, and particularly of human
and rodent origin. Also encompassed by the present invention is an
inhibitor or enhancer of Acrp30. The present invention further relates
to a method of identifying inhibitors or enhancers of Acrp30. Isolation
of Acrp30 makes it possible to detect Acrp30 or adipocytes in a sample
(e.g., test sample). In addition, the present invention relates to a
method of regulating the energy balance (e.g., nutritional status) of a
mammal by administering to the mammal an inhibitor or enhancer of the
Acrp30.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:18995 USPATFULL
TITLE: DNA encoding a novel serum protein produced exclusively
in adipocytes
INVENTOR(S): Scherer, Philipp E., Watertown, MA, United States
Lodish, Harvey F., Brookline, MA, United States
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869330		19990209
APPLICATION INFO.:	US 1995-463911		19950605 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Myers, Carla J.		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1023		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 5 USPATFULL on STN

TI Process for preparing co-poly(amides/peptides)
AB A process for preparing a co-poly(amide/peptide) by reacting
polymeric or oligomeric polypeptides and polymeric or oligomeric
polyamides in the presence of an effective amount of one or more aryl
phosphoryl azide compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 91:66850 USPATFULL

TITLE: Process for preparing co-poly(amides/peptides)
 INVENTOR(S): Bhattacharjee, Himangshu R., Randolph, NJ, United States
 Williams, Jon I., Robbinsville, NJ, United States
 Swerdloff, Michael D., Princeton, NJ, United States
 Berenbaum, Morris B., Summit, NJ, United States
 PATENT ASSIGNEE(S): Allied-Signal Inc., Morris Township, Morris County, NJ,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5041497		19910820
APPLICATION INFO.:	US 1989-335243		19890410 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Kishore, G. S.		
LEGAL REPRESENTATIVE:	Webster, Darryl L., Stewart, Richard C.		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
LINE COUNT:	995		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 5 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
 TI New peptides that regulate the degradation of type II collagen, useful for
 diagnosing and treating for e.g. osteoarthritis, rheumatoid arthritis,
 post-traumatic osteoarthritis, idiopathic osteoarthritis or eye diseases.
 AN 2004-316460 [29] WPIDS
 AB WO2004031206 A UPAB: 20040505
 NOVELTY - An isolated or purified peptide comprising a fully
 defined amino acid sequence of CB12, CB12-I, CB12-II, CB12-III, CB12-IV,
 Pro6, Pro15, Pro18 or Pro21, or its fragment, conservatively substituted
 variant, mimetic, inhibitor or homologue, is new. The peptide
 alters the rate of degradation of type II collagen or the rate of
 chondrocyte hypertrophy.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
 following:
 (1) a peptide dimer or trimer consisting of 2 or 3
 peptides, respectively, where each peptide is selected from the
 peptides cited above;
 (2) a pharmaceutical composition comprising a pharmaceutical carrier
 and at least one of the peptide inhibitors cited above;
 (3) a method of regulating collagen turnover;
 (4) a method of identifying a peptide mimetic of a
 peptide fragment of collagen capable of decreasing the degradation
 of the collagen in a biological sample;
 (5) an isolated or purified antibody that specifically binds to an
 epitope of the peptide or its antigenic fragment;
 (6) a method of diagnosing a disease selected from osteoarthritis,
 rheumatoid arthritis, post-traumatic osteoarthritis, idiopathic
 osteoarthritis and eye disease;
 (7) a method of inhibiting chondrocyte hypertrophy in a subject; and
 (8) a method of screening for a compound capable of inhibiting
 collagen breakdown.
 ACTIVITY - Osteopathic; Antiarthritic; Antirheumatic;
 Ophthalmological. No biological data given.
 MECHANISM OF ACTION - Gene therapy.
 USE - The pharmaceutical composition is useful for reducing collagen
 matrix turnover in mammals, particularly humans, or for reducing
 degradation of one or more collagen proteins. The antibody is used to
 inhibit the activity of the peptide, to identify inhibitors of
 the generation of the peptide, or to identify a subject at risk
 for rapid or slow progression of a disease responding to therapy designed

to arrest cartilage degradation or at risk for a disease by showing of early pre-clinical changes prior to clinical presentation of the disease, where the disease is selected from osteoarthritis, rheumatoid arthritis, post-traumatic osteoarthritis, idiopathic osteoarthritis and eye disease. In addition, the antibody is used to detect the release of type II collagen degradation products in body fluids, e.g. tissue extracts, serum, synovial fluid or urine (all claimed). The composition and methods may be used for diagnosing and treating such diseases.

Dwg.0/12

ACCESSION NUMBER: 2004-316460 [29] WPIDS
 DOC. NO. CPI: C2004-120061
 TITLE: New peptides that regulate the degradation of type II collagen, useful for diagnosing and treating for e.g. osteoarthritis, rheumatoid arthritis, post-traumatic osteoarthritis, idiopathic osteoarthritis or eye diseases.
 DERWENT CLASS: B04 D16
 INVENTOR(S): POOLE, A R
 PATENT ASSIGNEE(S): (SHRI-N) SHRINERS HOSPITALS FOR CHILDREN
 COUNTRY COUNT: 107
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004031206	A2	20040415	(200429)*	EN	74
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 2004122209	A1	20040624	(200442)		
AU 2003275294	A1	20040423	(200465)		
EP 1578776	A2	20050928	(200563)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
JP 2006501302	W	20060112	(200604)		48
KR 2005067402	A	20050701	(200643)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004031206	A2	WO 2003-US30744	20030930
US 2004122209	A1 Provisional	US 2002-414332P	20020930
		US 2003-674065	20030930
AU 2003275294	A1	AU 2003-275294	20030930
EP 1578776	A2	EP 2003-759570	20030930
		WO 2003-US30744	20030930
JP 2006501302	W	WO 2003-US30744	20030930
		JP 2004-541865	20030930
KR 2005067402	A	WO 2003-US30744	20030930
		KR 2005-705376	20050328

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003275294	A1 Based on	WO 2004031206
EP 1578776	A2 Based on	WO 2004031206
JP 2006501302	W Based on	WO 2004031206
KR 2005067402	A Based on	WO 2004031206

PRIORITY APPLN. INFO: US 2002-414332P 20020930; US
2003-674065 20030930

=> d his

(FILE 'HOME' ENTERED AT 17:16:09 ON 29 SEP 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT
17:18:51 ON 29 SEP 2006

L1 0 S PEPTIDE AND (DECREASE TYPE II COLLAGEN DEGRADATION)
L2 0 S PEPTIDE AND (DECREASE CHONDROCYTE HYPERTROPHY)
 E POOLE, R/AU
L3 11499 S PEPTIDE AND HYDROXYLATION
L4 5 S L3 AND (GLY-X-PRO)

=> s l3 and (decrease type II collagen degradation)

L5 0 L3 AND (DECREASE TYPE II COLLAGEN DEGRADATION)

Refine Search

Search Results -

Terms	Documents
L4 and L3	4

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L5

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, September 29, 2006

[Purge Queries](#)

[Printable Copy](#)

[Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L5</u>	L4 and l3	4	<u>L5</u>
<u>L4</u>	poole.in.	1121	<u>L4</u>
<u>L3</u>	L2 and peptide	57784	<u>L3</u>
<u>L2</u>	L1 and (decreasing chondrocyte hypertrophy rates)	1129983	<u>L2</u>
<u>L1</u>	degradation of type II collagen	2791023	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 6158431 A

L5: Entry 1 of 4

File: USPT

Dec 12, 2000

US-PAT-NO: 6158431
DOCUMENT-IDENTIFIER: US 6158431 A

TITLE: Portable systems and methods for delivery of therapeutic material to the pulmonary system

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Poole</u> ; Trent A.	Amherst	MA		

US-CL-CURRENT: 128/203.12; 128/200.16, 128/200.18, 128/200.21, 128/203.26, 128/203.27

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 2. Document ID: US 6132976 A

L5: Entry 2 of 4

File: USPT

Oct 17, 2000

US-PAT-NO: 6132976
DOCUMENT-IDENTIFIER: US 6132976 A

TITLE: Immunoassays for the measurement of collagen denaturation and cleavage in cartilage

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Poole</u> ; Anthony Robin	Baie d'Urfe			CA
Hollander; Anthony Peter	Greystones			GB
Billinghurst; R. Clark	Fort Collins	CO		

US-CL-CURRENT: 435/7.1; 424/1.49, 424/9.3, 424/9.34, 435/23, 435/328, 435/331, 435/7.9, 435/7.92, 435/975, 436/518, 530/326, 530/327, 530/328, 530/388.1, 530/388.85, 530/391.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 3. Document ID: US 5580855 A

L5: Entry 3 of 4

File: USPT

Dec 3, 1996

US-PAT-NO: 5580855
DOCUMENT-IDENTIFIER: US 5580855 A

TITLE: Peptides

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ferreira; Sergio H.	Est. Sao Paulo			BR
Bristow; Adrian F.	Hertfordshire			GB2
<u>Poole</u> ; Stephen	London			GB2

US-CL-CURRENT: 514/18; 530/331

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 4. Document ID: US 5389615 A

L5: Entry 4 of 4

File: USPT

Feb 14, 1995

US-PAT-NO: 5389615

DOCUMENT-IDENTIFIER: US 5389615 A

** See image for Certificate of Correction **

TITLE: Peptides and pharmaceutical composition thereof in the treatment of pain

DATE-ISSUED: February 14, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ferreira; Sergio H.	Est. Sao Paulo			BR
Bristow; Adrian F.	Hertfordshire			GB2
<u>Poole</u> ; Stephen	London			GB2

US-CL-CURRENT: 514/18; 530/331

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L4 and L3	4

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)